Global Non-Radiographic Axial Spondyloarthritis Therapeutics Market - Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Sep 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Non-Radiographic Axial Spondyloarthritis Therapeutics Market Treatment Type (Medication, Surgery, Physical Therapy), Route of Administration Type (Oral, Intravenous, Subcutaneous), Drugs (Secukinumab, Etanercept, Infliximab and Others), Routes of Administration (Oral, Intravenous, Subcutaneous), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis: Global Non-Radiographic Axial Spondyloarthritis Therapeutics Market

Global non-radiographic axial spondyloarthritis therapeutics market is rising gradually registering a substantial in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. The emergence of drugs used in the treatment of celiac disease, inflammatory bowel disease, hyperthyroidism, chronic obstructive pulmonary disease (COPD) and bone marrow cancer, growing aging population are the key drivers for market growth.

Market Definition: Global Non-Radiographic Axial Spondyloarthritis Therapeutics Market

Non-radiographic axial spondyloarthritis is a type of inflammatory arthritis, a hetrogenous group of autoimmune disorders that causes pain in lower back. The non-radiographic means that the symptoms or inflammation will not visible on x-ray (radiograph) but can show on MRI (magnetic resonance imaging) scan however it can negative too and axial spondyloarthritis means arthritis affect mainly on the spine. The patients with non- radiographic axial spondyloarthritis experience the severe back pain.

According to the statistics puplished in the UCB S.A., an estimated adult population of non-radiographic axial spondyloarthritis is up to 0.5% to 1.4%. Growing incidence of non-radiographic axial spondyloarthritis, accelerating demand of novel therapies and treatment are the key drivers for market growth

Market Drivers

  • Increases prevalence of non-radiographic axial spondyloarthritis worldwide can enhance the market growth
  • Vulnerable adult population can also act as a market driver

  • Accelerates demand of novel therapies and newer development is driving the growth of this market

  • Strategic collaboration and licensing deal between the companies safety is enhancing the market growth

Market Restraints

  • Effective treatment is either unavailable or unaffordable.
  • Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market

  • Inadequate knowledge about non-radiographic axial spondyloarthritis in some developing countries

Segmentation: Global Non-Radiographic Axial Spondyloarthritis Therapeutics Market

By Treatment Type

  • Medication

    • Calcium and vitamin D supplements
    • Nonsteroidal Anti-Inflammatory Drugs
    • Others

  • Surgery
  • Physical Therapy

By Drugs

  • Secukinumab
  • Etanercept
  • Infliximab
  • Others

By Route of Administration

  • Oral
  • Intravenous
  • Subcutaneous

By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

In June 2019, Kyowa Kirin Co., Ltd reported positive results of phase III, multi-regional, randomized, double-blind, placebo-controlled clinical study for brodalumab (KHK4827) evaluating for the treatment of non-radiographic axial spondyloarthritis. The trial has demonstrated that brodalumab was well tolerated in 16 weeks and effective. If successful, will be a novel option for the treatment of non-radiographic axial spondyloarthritis.

In March 2019, UCB SA received the US FDA approval for Cimzia (certolizumab pegol), EGylated anti-TNF (Tumor Necrosis Factor) for the treatment of non-radiographic axial spondyloarthritis.The FDA approval of Cimzia represents the significant treatment options for patients suffering from osteoporosis non-radiographic axial spondyloarthritis across the globe.

Competitive Analysis:

Global non-radiographic axial spondyloarthritis therapeutics market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global non-radiographic axial spondyloarthritis therapeutics market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global non-radiographic axial spondyloarthritis therapeutics market are Kyowa Kirin Co., Ltd., Allergan, Amgen Inc, Astellas Pharma Inc, AstraZeneca, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Teijin Pharma Limited, Stelis Biopharma, Radius Health, Inc, Pfizer Inc, Ono Pharmaceutical Co., Ltd, Novartis AG, Mochida Pharmaceutical Co., Ltd, Mereo BioPharma Group plc, Merck & Co., Inc, Gedeon Richter (UK) Ltd, F. Hoffmann-La Roche Ltd, Novo Nordisk A/S, Cipla Inc, UCB SA, Teva Pharmaceutical Industries Ltd and among others.

Research Methodology: Global Non-Radiographic Axial Spondyloarthritis Therapeutics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of Global non-radiographic axial spondyloarthritis therapeutics market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19